Matthias Kappler1, Felicitas Nagel2, Maria Feilcke3, Gabriele Heilig4, Ann-Christin Grimmelt5, Ingo Pawlita6, Armin Irnstetter7, Jenna Hildebrandt8, Helen Burmester9, Caroline Kröner10, Matthias Griese11. 1. Children's University Hospital of the Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. Electronic address: Matthias.Kappler@med.uni-muenchen.de. 2. Children's University Hospital of the Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. Electronic address: Felicitas.Nagel@med.uni-muenchen.de. 3. Children's University Hospital of the Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. Electronic address: Maria.Feilcke@med.uni-muenchen.de. 4. Children's University Hospital of the Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. Electronic address: Gabriele.Heilig@med.uni-muenchen.de. 5. Children's University Hospital of the Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. Electronic address: Ann-Christin.Grimmelt@med.uni-muenchen.de. 6. Children's University Hospital of the Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. Electronic address: Ingo.Pawlita@med.uni-muenchen.de. 7. Children's University Hospital of the Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. Electronic address: Armin.Irnstetter@med.uni-muenchen.de. 8. Children's University Hospital of the Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. Electronic address: Jenna.Hildebrandt@med.uni-muenchen.de. 9. Children's University Hospital of the Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. Electronic address: Helen.Burmester@med.uni-muenchen.de. 10. Children's University Hospital of the Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. Electronic address: Caroline.Kroener@med.uni-muenchen.de. 11. Children's University Hospital of the Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. Electronic address: Matthias.Griese@med.uni-muenchen.de.
Abstract
BACKGROUND: Patient dependent parameters to predict the long-term success of early eradication treatment of Pseudomonas aeruginosa have not yet been defined. For this purpose we assessed serum antibodies against P. aeruginosa in CF patients after early eradication treatment. METHODS: Retrospective analyses of all consecutive patients with first P. aeruginosa detection 2005 to 2008. Absence of P. aeruginosa in the third year was defined as successful long-term eradication. Main outcome was to determine the predictive value of P. aeruginosa antibody results one year after initiation of early eradication treatment using antibodies against alkaline protease, elastase, and exotoxin A with regard to long-term success of eradication treatment. RESULTS: Antibodies against P. aeruginosa correlated well with success of eradication; positive and negative predictive values after one year were 75% and 82% respectively. The incidence of new detection of P. aeruginosa was 8.5%. Long-term eradication was successful in 32 of 53 patients (60%). CONCLUSIONS: Determination of serum antibodies against P. aeruginosa one year after first detection of P. aeruginosa and early eradication treatment can predict success of long-term eradication.
BACKGROUND:Patient dependent parameters to predict the long-term success of early eradication treatment of Pseudomonas aeruginosa have not yet been defined. For this purpose we assessed serum antibodies against P. aeruginosa in CFpatients after early eradication treatment. METHODS: Retrospective analyses of all consecutive patients with first P. aeruginosa detection 2005 to 2008. Absence of P. aeruginosa in the third year was defined as successful long-term eradication. Main outcome was to determine the predictive value of P. aeruginosa antibody results one year after initiation of early eradication treatment using antibodies against alkaline protease, elastase, and exotoxin A with regard to long-term success of eradication treatment. RESULTS: Antibodies against P. aeruginosa correlated well with success of eradication; positive and negative predictive values after one year were 75% and 82% respectively. The incidence of new detection of P. aeruginosa was 8.5%. Long-term eradication was successful in 32 of 53 patients (60%). CONCLUSIONS: Determination of serum antibodies against P. aeruginosa one year after first detection of P. aeruginosa and early eradication treatment can predict success of long-term eradication.
Authors: Joshua T Thaden; Ashley E Keller; Norah J Shire; M Margarita Camara; Linda Otterson; Mike Huband; Caitlin M Guenther; Wei Zhao; Paul Warrener; C Kendall Stover; Vance G Fowler; Antonio DiGiandomenico Journal: J Infect Dis Date: 2015-09-02 Impact factor: 5.226